A PCR Allelic Competitive Extension assay for CYP2C19*2, *3 and *17 was tested on 30 DNA samples against TaqMan. Concordance was 100%, with clear genotype clusters. Genotypes were *1/*1 53.3%, *1/*2 30.0%, *1/*3 10.0% and *2/*2 6.7%; *17 was absent. Reagent cost was reported as USD 4.34 or THB 135 per sample. This is encouraging proof of concept, not yet broad clinical validation.
Key findings
- PACE matched TaqMan in all 30 samples. • Reported reagent cost was about THB 135 for three variants. • No *17 sample was present, so real positive classification for that allele was not tested.
Why this matters globally
With further validation, the method could lower pharmacogenomic costs in resource-limited systems and support safer drug selection.
Thai researcher contribution
Chiang Mai University develops a lower-cost tool tailored to practical Thai laboratory constraints.
Limitations to consider
The study was small, included no *17 positive, and did not report inter-run reproducibility, detection limits or complex clinical-sample performance.